Abstract
Over 90% of leukemic blasts in patients with acute lymphoblastic leukemia express the marker CD22. Inotuzumab ozogamicin (INO) is a CD22-directed humanized monoclonal antibody conjugated to the potent cytotoxin, calicheamicin, via an acid labile linker. INO has shown high rates of response in the treatment of relapsed and refractory (R/R) ALL in single-Agent studies, with fewer adverse effects than traditional cytotoxic chemotherapy. Given this experience, studies are now being done to evaluate INO in combination with low-intensity chemotherapy as frontline treatment for older adults with ALL and patients with R/R disease. Herein we will discuss the use of INO in the treatment of acute lymphoblastic leukemia.
| Original language | English (US) |
|---|---|
| Pages (from-to) | 329-334 |
| Number of pages | 6 |
| Journal | Expert review of hematology |
| Volume | 9 |
| Issue number | 4 |
| DOIs | |
| State | Published - Apr 2 2016 |
Keywords
- CD22
- Inotuzumab
- acute lymphoblastic leukemia
- refractory
- relapsed
ASJC Scopus subject areas
- Hematology